Navigation Links
SPO Medical Announces Major Sales Milestone
Date:10/22/2007

Company Sells 100,000th Pulse Oximetry Unit

NEW YORK, Oct. 22 /PRNewswire-FirstCall/ -- SPO Medical Inc. (OTC Bulletin Board: SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced that is has sold its 100,000th pulse oximetry unit. This sales milestone has been achieved within three years of the company's first introduction of the commercial product.

The bulk of the 100,000 units sold include the patented technology of PulseOx 5500(TM) and the PulseOx 7500(TM), a new product that was commercially launched during the second quarter of 2007. First introduced at the end of 2004, the PulseOx 5500(TM) is a spot check finger monitor for the medical market and is sold primarily to homecare users as well as to hospitals, physicians and emergency care facilities to monitor heart rate and blood oxygenation levels. The PulseOx 7500(TM) device is sold to physicians and sleep clinics primarily for pre-screening of sleep apnea; a medical condition with fast growing awareness throughout the industrialized world.

SPO Medical intends to announce two new professional oximetry devices this year for the hospital and physician markets. These new products will be first shown during mid-November at the annual Medica Exposition in Dusseldorf, Germany which is the world's largest medical international trade fair for supplies of medical devices; this will be followed by the American Association for Respiratory Care (AARC) International Respiratory Congress in Florida in December of this year.

"We are pleased to announce this major sales milestone and look forward to further growing the company with the addition of new products expanding our technology to a number of market applications" said Michael Braunold, President and CEO of SPO Medical Inc. "The launch of two new oximetry devices later this year is a further testament to our commitment and implementation of our strategy of introducing innovative products to the marketplace."

For additional details of SPO Medical' attendance at commercial forums, please visit our web site at http://www.spomedical.com

About SPO Medical

SPO Medical (SPOM) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spomedical.com.

Safe Harbor:

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the availability of working capital, changes in costs and the availability of goods and services, the introduction of competing products, delays in planned product launches, changes in our operating strategy or development plans, our ability to attract and retain qualified personnel, the possible fluctuation and volatility of our operating results, financial condition and stock price and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006. We undertake no obligation to revise or update any forward-looking statement for any reason.

SPO Medical Contact: Seventh Circle Consulting Contact:

Michael Braunold, CEO Christine J. Petraglia

braunold@spomedical.com christine@seventhcirclellc.com

011-972-9-7643570 1-646-354-888


'/>"/>
SOURCE SPO Medical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016 The research report ... players in the  Global Label-Free Array Systems Market  accounted ... in 2015. Players such as Biacore, Agilent Technologies, ForteBio, ... in the global market due to their unmatched product ... Product upgrades and timely product launches are expected to ...
(Date:12/9/2016)... Dec. 9, 2016 China Cord Blood Corporation (NYSE: ... China,s leading provider of cord blood collection, laboratory ... today announced the results of its 2016 Annual General Meeting, ... S.A.R., China . At ... the re-appointment of KPMG Huazhen LLP as the independent auditors ...
(Date:12/9/2016)... According to a new market research report "Oligonucleotide Synthesis Market ... (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, ... is expected to reach USD 2.20 Billion by 2021 from USD ... forecast period. Continue Reading ... ...
(Date:12/8/2016)... This report analyzes the worldwide markets for Biostimulants ... Amino, & Fulvic), Extract Based, and Others. The report also ... & Turf, Row Crops, and Others. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and forecasts are ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
Breaking Biology News(10 mins):